cfOncoXpress predicts tumor gene expression from cell-free DNA whole-genome sequences using fragmentation patterns and copy number aberrations, outperforming existing methods in prostate and breast cancers.

bioRxiv · Oct 31, 2025 · PreprintGenomics

Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer

Marjorie L. Roskes, Alexander Martinez‐Fundichely, Sandra M. Cohen, Metin Balaban, Chen Khuan Wong, Weiling Li, Tonatiuh A. Gonzalez, Anisha B. Tehim, Hao Xu, Shahd ElNaggar, Matthew A. Myers, Rohan Bareja, Princesca Dorsaint, Kathryn Gorski, Muhammad Imran Asad, , Ekta Khurana

The paper identifies genomic alterations in the YAP/TAZ pathway associated with stem cell-like castration-resistant prostate cancer using transcriptomic and whole-genome sequencing data.

medRxiv · Jul 1, 2025 · PreprintGenetic & Genomic Medicine

BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer.

Shipra Shukla, Dan Li, Woo Hyun Cho, Dana M. Schoeps, Holly M. Nguyen, Jennifer L. Conner, Marjorie L. Roskes, Anisha B. Tehim, Gabriella Bayshtok, Mohini R. Pachai, Juan Yan, Nicholas A. Teri, Eric Campeau, Sarah Attwell, Patrick Trojer, , Yu Chen

This study identifies BET inhibitors as effective against GI transcriptome-positive CRPC by targeting HNF1A and HNF4G, improving outcomes in preclinical models.

Journal of Clinical Investigation · Jun 24, 2025Peer-reviewedCancer Biology